Trial Profile

Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Oct 2024 Status changed from active, no longer recruiting to discontinued.
04 May 2023 According to an Endogena Therapeutics media release, the first patient started treatment in July 2022 and topline interim data is anticipated in early 2024.
04 May 2023 According to an Endogena Therapeutics media release, company announced that it has completed patient enrollment ahead of schedule in this trial, with the dose-escalation stage completed in April, the ongoing trial is now in the expansion cohort stage.The trial is being conducted across five US sites.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com